Skip to Content

Peginesatide use while Breastfeeding

Drugs containing Peginesatide: Omontys

Medically reviewed on September 7, 2017.

Peginesatide Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of peginesatide during breastfeeding. Because of its large molecular weight of 4900 daltons, excretion into breastmilk should be minimal and it would not be expected to be absorbed from breastmilk by the infant. If peginesatide is required by the mother of an older infant, it is not a reason to discontinue breastfeeding, but until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Epoetin Alfa

References

Peginesatide Identification

Substance Name

Peginesatide

CAS Registry Number

913976-27-9

Drug Class

Colony-Stimulating Factors

Hematinics

Hematopoietic Cell Growth Factors

Administrative Information

LactMed Record Number

996

Disclaimer

Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide